MiMedx Group (NASDAQ:MDXG – Get Free Report) released its earnings results on Wednesday. The company reported $0.07 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.07, Zacks reports. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%.
MiMedx Group Price Performance
MDXG stock traded up $0.05 during mid-day trading on Wednesday, hitting $8.01. The company had a trading volume of 562,154 shares, compared to its average volume of 563,991. The company has a 50-day moving average price of $8.78 and a 200 day moving average price of $7.68. MiMedx Group has a 12-month low of $5.47 and a 12-month high of $10.14. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of 14.56 and a beta of 1.94. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10.
Analysts Set New Price Targets
Separately, StockNews.com downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $12.00.
About MiMedx Group
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.
Further Reading
- Five stocks we like better than MiMedx Group
- Manufacturing Stocks Investing
- Buffett’s on the Sidelines – Should You Follow?
- What Are Dividend Achievers? An Introduction
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.